PharmaMar: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
'''PharmaMar''' is a | {{DISPLAYTITLE:PharmaMar}} | ||
== Overview == | |||
[[File:Pharma_Mar_logo.svg|thumb|right|PharmaMar logo]] | |||
'''PharmaMar''' is a Spanish biopharmaceutical company that specializes in the discovery and development of marine-derived drugs. The company is a leader in the field of marine biotechnology and focuses on oncology, central nervous system disorders, and other therapeutic areas. | |||
== History == | == History == | ||
PharmaMar was founded in 1986 with the aim of | PharmaMar was founded in 1986 as a subsidiary of the Zeltia Group, with the aim of exploring the potential of marine organisms for pharmaceutical development. Over the years, PharmaMar has developed a robust pipeline of drugs, with several products reaching the market. | ||
== Research and Development == | |||
PharmaMar's research is centered on the discovery of novel compounds from marine organisms. The company has a unique library of marine samples collected from various oceanic environments. These samples are screened for bioactive compounds that can be developed into therapeutic agents. | |||
=== Marine Biotechnology === | |||
Marine biotechnology is a key area of focus for PharmaMar. The company utilizes advanced techniques in molecular biology and chemistry to isolate and characterize compounds from marine organisms. This approach has led to the discovery of several promising drug candidates. | |||
== Products == | == Products == | ||
PharmaMar | PharmaMar has developed several drugs that are used in the treatment of cancer and other diseases. Some of the notable products include: | ||
== | * '''Yondelis''' (trabectedin) - An anticancer drug used in the treatment of soft tissue sarcoma and ovarian cancer. | ||
PharmaMar | * '''Aplidin''' (plitidepsin) - A drug under investigation for the treatment of multiple myeloma and other cancers. | ||
== Collaborations and Partnerships == | |||
PharmaMar collaborates with various academic institutions, research organizations, and pharmaceutical companies to advance its drug development programs. These partnerships are crucial for the clinical development and commercialization of its products. | |||
== | == Headquarters == | ||
PharmaMar | PharmaMar is headquartered in [[Madrid]], [[Spain]]. The company operates globally, with a presence in several countries through its subsidiaries and partnerships. | ||
== | == Related pages == | ||
* [[ | * [[Biotechnology]] | ||
* [[Oncology]] | * [[Oncology]] | ||
* [[ | * [[Pharmaceutical industry]] | ||
* [[Marine biology]] | |||
* [ | |||
[[Category:Pharmaceutical companies]] | [[Category:Pharmaceutical companies of Spain]] | ||
[[Category:Biotechnology companies]] | [[Category:Biotechnology companies]] | ||
[[Category:Companies established in 1986]] | [[Category:Companies established in 1986]] | ||
Latest revision as of 10:51, 15 February 2025
Overview[edit]
PharmaMar is a Spanish biopharmaceutical company that specializes in the discovery and development of marine-derived drugs. The company is a leader in the field of marine biotechnology and focuses on oncology, central nervous system disorders, and other therapeutic areas.
History[edit]
PharmaMar was founded in 1986 as a subsidiary of the Zeltia Group, with the aim of exploring the potential of marine organisms for pharmaceutical development. Over the years, PharmaMar has developed a robust pipeline of drugs, with several products reaching the market.
Research and Development[edit]
PharmaMar's research is centered on the discovery of novel compounds from marine organisms. The company has a unique library of marine samples collected from various oceanic environments. These samples are screened for bioactive compounds that can be developed into therapeutic agents.
Marine Biotechnology[edit]
Marine biotechnology is a key area of focus for PharmaMar. The company utilizes advanced techniques in molecular biology and chemistry to isolate and characterize compounds from marine organisms. This approach has led to the discovery of several promising drug candidates.
Products[edit]
PharmaMar has developed several drugs that are used in the treatment of cancer and other diseases. Some of the notable products include:
- Yondelis (trabectedin) - An anticancer drug used in the treatment of soft tissue sarcoma and ovarian cancer.
- Aplidin (plitidepsin) - A drug under investigation for the treatment of multiple myeloma and other cancers.
Collaborations and Partnerships[edit]
PharmaMar collaborates with various academic institutions, research organizations, and pharmaceutical companies to advance its drug development programs. These partnerships are crucial for the clinical development and commercialization of its products.
Headquarters[edit]
PharmaMar is headquartered in Madrid, Spain. The company operates globally, with a presence in several countries through its subsidiaries and partnerships.
